TY - JOUR
T1 - An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
AU - Fader, Amanda Nickles
AU - Starks, David
AU - Gehrig, Paola A.
AU - Secord, Angeles Alvarez
AU - Frasure, Heidi E.
AU - O'Malley, David M.
AU - Tuller, Erin R.
AU - Rose, Peter G.
AU - Havrilesky, Laura J.
AU - Moore, Kathleen N.
AU - Huh, Warner K.
AU - Axtell, Allison E.
AU - Kelley, Joseph L.
AU - Zanotti, Kristine M.
PY - 2009/11
Y1 - 2009/11
N2 - Objectives: Stage I-II uterine papillary serous carcinoma (UPSC) patients have a significant risk for extrapelvic recurrence. However, clinicopathologic risk factors for recurrence are not well understood. This study was undertaken to define the prognostic factors for recurrence and survival in patients with early-stage UPSC. Methods: A retrospective, multi-institution analysis of surgically staged I-II UPSC patients was performed. Patients were treated by various adjuvant modalities. Age, race, sub-stage, percentage UPSC histology, lymphvascular space invasion (LVSI), tumor size and adjuvant treatment modality were evaluated for their effect on recurrence and survival outcomes. Results: We identified 206 patients. Forty patients (19.4%) had 5-49% UPSC, 55 (26.7%) had 50-99% and 111 patients (53.9%) had 100% UPSC in their respective uterine specimens. Twenty one percent of patients experienced a primary recurrence. On univariate analysis, age, increasing %UPSC, LVSI, and tumor size were not significantly associated with recurrence or progression-free survival (PFS). However, substage (p = 0.005) and treatment with platinum/taxane-based chemotherapy (p = 0.001) were associated with recurrence/PFS. On multivariate analysis, only chemotherapy (p = 0.01) was a significant factor affecting PFS, whereas age (p = 0.05), substage (p = 0.05), and chemotherapy (p = 0.02) were associated with overall survival. Conclusions: Traditional risk factors for recurrence and survival in patients with early-stage endometrial cancer may not be relevant in patients with UPSC. Patients with any percentage UPSC in their uterine specimens are at a significant risk for recurrence and poor survival outcomes. Given that current clinicopathologic data does not accurately identify women most likely to benefit from adjuvant therapy, alternative prognostic markers based on novel techniques should be explored.
AB - Objectives: Stage I-II uterine papillary serous carcinoma (UPSC) patients have a significant risk for extrapelvic recurrence. However, clinicopathologic risk factors for recurrence are not well understood. This study was undertaken to define the prognostic factors for recurrence and survival in patients with early-stage UPSC. Methods: A retrospective, multi-institution analysis of surgically staged I-II UPSC patients was performed. Patients were treated by various adjuvant modalities. Age, race, sub-stage, percentage UPSC histology, lymphvascular space invasion (LVSI), tumor size and adjuvant treatment modality were evaluated for their effect on recurrence and survival outcomes. Results: We identified 206 patients. Forty patients (19.4%) had 5-49% UPSC, 55 (26.7%) had 50-99% and 111 patients (53.9%) had 100% UPSC in their respective uterine specimens. Twenty one percent of patients experienced a primary recurrence. On univariate analysis, age, increasing %UPSC, LVSI, and tumor size were not significantly associated with recurrence or progression-free survival (PFS). However, substage (p = 0.005) and treatment with platinum/taxane-based chemotherapy (p = 0.001) were associated with recurrence/PFS. On multivariate analysis, only chemotherapy (p = 0.01) was a significant factor affecting PFS, whereas age (p = 0.05), substage (p = 0.05), and chemotherapy (p = 0.02) were associated with overall survival. Conclusions: Traditional risk factors for recurrence and survival in patients with early-stage endometrial cancer may not be relevant in patients with UPSC. Patients with any percentage UPSC in their uterine specimens are at a significant risk for recurrence and poor survival outcomes. Given that current clinicopathologic data does not accurately identify women most likely to benefit from adjuvant therapy, alternative prognostic markers based on novel techniques should be explored.
KW - Prognostic factors
KW - Recurrence
KW - Uterine papillary serous carcinoma
UR - http://www.scopus.com/inward/record.url?scp=70349737557&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349737557&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2009.07.030
DO - 10.1016/j.ygyno.2009.07.030
M3 - Article
C2 - 19712966
AN - SCOPUS:70349737557
SN - 0090-8258
VL - 115
SP - 244
EP - 248
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 2
ER -